Today: 3 March 2026
Subscribe

Khadija Saeed

A dedicated markets reporter, she covers stocks, macroeconomics, and major business developments with a sharp eye for detail and accuracy.

U.S. Bancorp (USB) Stock on December 1, 2025: Q3 Earnings Beat, 4%+ Dividend and 2026 Forecasts

U.S. Bancorp (USB) Stock on December 1, 2025: Q3 Earnings Beat, 4%+ Dividend and 2026 Forecasts

U.S. Bancorp closed at $49.41 on December 1, 2025, after reporting record Q3 revenue of $7.33 billion and net income of $2 billion, both above analyst expectations. The stock yields about 4.2% and has outperformed regional bank peers over the past three months. Shares remain below year-ago levels and face ongoing scrutiny over insider sales and regulatory risks.
2 December 2025
····
General Dynamics Stock (GD) in December 2025: Earnings Beats, Massive Backlog and a New Legal Challenge

General Dynamics Stock (GD) in December 2025: Earnings Beats, Massive Backlog and a New Legal Challenge

General Dynamics shares closed at $332.38 on December 1, down 2.71% but up 26% year-to-date. The company reported three straight quarters of double-digit earnings growth in 2025 and ended Q2 with a record $88.7 billion backlog. Shares remain about 7.8% below the October 24 high. A new legal issue has emerged as Wall Street interest climbs.
2 December 2025
··
Starbucks Stock (SBUX) on December 1, 2025: NYC Settlement, Union Strike and Wall Street’s 2026 Forecast

Starbucks Stock (SBUX) on December 1, 2025: NYC Settlement, Union Strike and Wall Street’s 2026 Forecast

Starbucks shares fell 2.5% to $84.91 on December 1 after agreeing to a $38.9 million New York City settlement over alleged violations of worker scheduling laws. The drop comes amid a nationwide union strike and split analyst views on the company’s outlook. Starbucks remains up 4.2% year-to-date but trades well below its 2021 peak.
2 December 2025
··
Bristol-Myers Squibb (BMY) Stock Today: Lawsuit Shock, Breyanzi Momentum and 2026 Forecast

Bristol-Myers Squibb (BMY) Stock Today: Lawsuit Shock, Breyanzi Momentum and 2026 Forecast

A U.S. federal judge allowed a $6.7 billion lawsuit against Bristol-Myers Squibb over its 2019 Celgene acquisition to proceed, rejecting the company’s motion to dismiss key claims. BMY shares closed at $49.18 on December 1, up 7–8% over five days, but remain down for the year. The company’s annual dividend yield is about 5%. New cell therapy approvals and strong ASH 2025 hematology data also drew investor attention.
2 December 2025
·
Newmont Stock Soars in 2025 as Gold Hits Records: Is NEM Still a Buy After UBS Lifts Target to $125?

Newmont Stock Soars in 2025 as Gold Hits Records: Is NEM Still a Buy After UBS Lifts Target to $125?

Newmont stock closed at $91.83 on December 1, 2025, more than doubling year-to-date after a 12% jump in November. UBS raised its price target to $125, citing strong gold prices and Newmont’s record free cash flow. The company posted Q3 net income of $1.8 billion and revenue of $5.52 billion, both beating estimates. Newmont has rapidly reduced debt and increased share buybacks.
2 December 2025
·
CVS Health Stock in December 2025: Price, Forecast, Dividend and Whether the Rally Still Has Room to Run

CVS Health Stock in December 2025: Price, Forecast, Dividend and Whether the Rally Still Has Room to Run

CVS Health shares closed at $79.10 on December 1, 2025, down 1.6% and about 7% below their 52-week high. The stock is up nearly 79% year-to-date. Q3 revenue rose 7.8% to $102.9 billion, with adjusted EPS of $1.60 but a GAAP loss per share of –$3.13 due to a $5.7 billion non-cash goodwill impairment. CVS’s trailing P/E ratio spiked above 200 from the one-time charge.
2 December 2025
··
CME Group (CME) Stock: Outage Fallout, Record Volumes and 2026 Price Targets Explained

CME Group (CME) Stock: Outage Fallout, Record Volumes and 2026 Price Targets Explained

CME Group halted trading for about 10 hours on November 28 after a cooling failure at a CyrusOne data center in Illinois, disrupting global futures and options markets. Shares closed at $279, down 0.9%, with a market cap over $100 billion. CME stock is up about 21% year-to-date, but some analysts warn it may be overvalued by up to 40%. The company paid $10.80 per share in dividends over the past year.
2 December 2025
·
Parker-Hannifin (PH) Stock Outlook December 2025: Aerospace Strength, $9.25B Filtration Deal and a Valuation Tug of War

Parker-Hannifin (PH) Stock Outlook December 2025: Aerospace Strength, $9.25B Filtration Deal and a Valuation Tug of War

Parker-Hannifin closed December 1, 2025, at about $856 per share, with a $109 billion market cap. The stock is up roughly 36% year-to-date, beating the S&P 500. Growth is driven by strong aerospace results and the $9.25 billion Filtration Group acquisition. Some models now estimate PH is overvalued by about 30%, though most analysts remain positive.
1 December 2025
·
KKR Stock Today (December 1, 2025): Earnings Beat, Analyst Targets and Private Credit Stress Test

KKR Stock Today (December 1, 2025): Earnings Beat, Analyst Targets and Private Credit Stress Test

KKR shares closed near $122.50 on December 1, up from autumn lows but still 28% below the January peak of $170.40. The firm reported a strong Q3 earnings beat and faces new regulatory scrutiny as it joins the Bank of England’s private credit stress test. Market cap stands at about $108 billion. The next $0.19 dividend is set for December 2.
1 December 2025
··
HCA Healthcare (HCA) Stock on December 1, 2025: Near All‑Time Highs, Upgraded Guidance and What Comes Next

HCA Healthcare (HCA) Stock on December 1, 2025: Near All‑Time Highs, Upgraded Guidance and What Comes Next

HCA Healthcare closed at about $503 on December 1, down 1% from Friday and just below its record high of $520 set in the prior session. Institutional investors shifted positions, with Dixon Mitchell raising its stake by 6.9% and others reducing holdings. The stock is up 71.5% year-to-date and trades at a discount to sector averages. Institutional holders control about 62.7% of shares.
1 December 2025
·
Honeywell (HON) Stock Today: Price, Earnings, Breakup Plan and 2026 Forecast (December 1, 2025)

Honeywell (HON) Stock Today: Price, Earnings, Breakup Plan and 2026 Forecast (December 1, 2025)

Honeywell closed at $190.22 on December 1, down 1% for the day and about 16% below its 52-week high. The company recently beat Q3 earnings estimates, raised full-year guidance, and completed the Solstice Advanced Materials spin-off. Bank of America double-downgraded the stock to Underperform, while most analysts still rate it a Buy. Honeywell plans to split into Aerospace and Automation firms by 2026.
1 December 2025
···
Wells Fargo (WFC) Stock on December 1, 2025: Price, Dividend, Lawsuit Settlement and 2025–2030 Forecast

Wells Fargo (WFC) Stock on December 1, 2025: Price, Dividend, Lawsuit Settlement and 2025–2030 Forecast

Wells Fargo shares closed at $85.4 on December 1, 2025, down just over half a percent, after hitting a record $88.54 in November. The bank reported Q3 net income of $5.6 billion, up from $5.1 billion a year earlier, and raised its medium-term ROTCE target to 17–18% after the Fed lifted its asset cap. Market cap stands near $270 billion. December 1 marked both a dividend payout and an $85 million class-action settlement.
1 December 2025
··
Verizon Communications Inc. (VZ) Stock in December 2025: Earnings, 7% Dividend Yield and Frontier Deal Update

Verizon Communications Inc. (VZ) Stock in December 2025: Earnings, 7% Dividend Yield and Frontier Deal Update

Verizon closed December 1, 2025, at $40–41 per share, with a $173 billion market cap and a 6.7–6.8% dividend yield. Third-quarter revenue reached $33.8 billion, up 1.5% year-over-year, while adjusted EPS was $1.21. Wireless service revenue rose to $21.0 billion. Total unsecured debt fell to $119.7 billion from $126.4 billion a year earlier.
1 December 2025
···
Union Pacific (UNP) Stock on December 1, 2025: Merger Risks, Dividend Strength and Wall Street’s 2026 Price Targets

Union Pacific (UNP) Stock on December 1, 2025: Merger Risks, Dividend Strength and Wall Street’s 2026 Price Targets

Union Pacific closed at $231.36 on December 1, 2025, valuing the company at $137 billion, with shares trading between $204.66 and $256.84 over the past year. Q3 adjusted EPS rose 12% to $3.08, net income climbed 9% to $1.8 billion, and operating revenue reached $6.24 billion. The company faces elevated regulatory and merger risk as it pursues an $85 billion Norfolk Southern deal.
1 December 2025
····
Texas Instruments (TXN) Stock on December 1, 2025: Earnings Hangover, $60 Billion Fab Bet and What Wall Street Expects Next

Texas Instruments (TXN) Stock on December 1, 2025: Earnings Hangover, $60 Billion Fab Bet and What Wall Street Expects Next

Texas Instruments shares traded near $168 on December 1, 2025, valuing the company at about $152 billion, down roughly 10% year-to-date and 16% over 12 months. Q3 revenue rose 14% to $4.74 billion, beating estimates, but the stock remains below its 52-week high as investors weigh heavy spending and a softer earnings outlook.
1 December 2025
··
Chevron (CVX) Stock Today: HSBC Upgrade, CPC Drone Attack Fallout and 2030 Cash‑Flow Roadmap

Chevron (CVX) Stock Today: HSBC Upgrade, CPC Drone Attack Fallout and 2030 Cash‑Flow Roadmap

Chevron shares traded at $152–153 on Monday after HSBC upgraded the stock to Buy and raised its price target to $169. The move follows a drone attack on a key export terminal and renewed focus on Chevron’s 2030 free-cash-flow plan. CVX yields 4.4–4.6% with a $1.71 quarterly dividend, and has returned 10.6% year to date. Market cap stands near $300 billion.
1 December 2025
··
AbbVie (ABBV) Stock in December 2025: Atogepant Breakthrough, Q3 Beat and 2026 Outlook After Medicare Price Cuts

AbbVie (ABBV) Stock in December 2025: Atogepant Breakthrough, Q3 Beat and 2026 Outlook After Medicare Price Cuts

AbbVie shares closed near $225 on December 1, 2025, valuing the company at about $400 billion. Q3 net revenue rose 9.1% to $15.78 billion, with adjusted EPS of $1.86 topping estimates. The company raised its 2025 profit forecast and approved a 5.5% dividend increase. Immunology sales climbed, while Humira revenue dropped below $1 billion.
1 December 2025
····
1 … 646 647 648 649 650 … 682
Go toTop